Abstract
Much of the familial aggregation of common cancer results from inherited susceptibility, but highly penetrant mutations in known genes cannot account for most of the excess. Some of the unexplained familial risk is presumably due to high-penetrance mutations in as yet unidentified genes, but polygenic mechanisms are likely to account for a greater proportion, particularly in breast cancer. This inference, coupled with technological developments, has led to a renaissance in association studies. Most such studies have evaluated small numbers of single-nucleotide polymorphisms (SNPs) in a few candidate genes, but reliable high-density oligonucleotide arrays and other novel techniques will allow genome-wide allelic association studies to be conducted. High-density genome-wide SNP analysis will include targets identified by structural considerations, as well as the growing list of candidate genes. In the longer term, high-throughput re-sequencing will be required to identify the rare pathogenic variants that may constitute the majority of low-penetrance alleles. The detection of low-penetrance cancer susceptibility genes will then be restricted mainly by the availability of large numbers of well-characterized cases and controls. Cancer patients with affected relatives are considerably more informative than unselected cases for such studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abecasis GR, Noguchi E, Heinzmann A, Traherne JA, Bhattacharyya S, Leaves NI, Anderson GG, Zhang Y, Lench NJ, Carey A, Cardon LR, Moffatt MF and Cookson WO . (2000). Am. J. Hum. Genet., 68, 191–197.
Anderson DE . (1974). Cancer, 34, 1090–1097.
Anglian Breast Cancer Study Group (2000). Br. J. Cancer, 83, 1301–1308.
Antoniou AC and Easton DF . (2003). Genet. Epidemiol., 25, 190–202.
Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, Brockmoller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Kihara M, Kremers P, Le Marchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg D, Seidegard J, Shields P, Strange RC, Stucker I, To-Figueras J, Brennan P and Taioli E . (2002). Carcinogenesis, 23, 1343–1350.
Bodmer WF, Bailey CJ, Bodmer J, Bussey HJR, Ellis A, Gorman P, Lucibello FC, Murday VA, Rider SH, Scambler P, Sheer D, Solomon E and Spurr NK . (1987). Nature, 328, 614–616.
Botstein D and Risch N . (2003). Nat. Genet., 33 (Suppl), 228–237.
Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olopade OI, Diaz MO, Kwiatkowski DJ, Piepkorn MW, Zone JJ and Skolnick MH . (1992). Science, 258, 1148–1152.
CHEK2 Breast Cancer Case-Control Consortium (2004). Am. J. Hum. Genet., 74, 1175–1182.
Collins A, Ennis S, Taillon-Miller P, Kwok PY and Morton NE . (2001). Hum. Mutat., 17, 255–262.
Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A and Lee EY . (1999). Oncogene, 18, 7883–7899.
DeMille MM, Kidd JR, Ruggeri V, Palmatier MA, Goldman D, Odunsi A, Okonofua F, Grigorenko E, Schulz LO, Bonne-Tamir B, Lu RB, Parnas J, Pakstis AJ and Kidd KK . (2002). Hum. Genet., 111, 521–537.
Dunning AM, Durocher F, Healey CS, Teare MD, McBride SE, Carlomagno F, Xu CF, Dawson E, Rhodes S, Ueda S, Lai E, Luben RN, Van Rensburg EJ, Mannermaa A, Kataja V, Rennart G, Dunham I, Purvis I, Easton D and Ponder BA . (2000). Am. J. Hum. Genet., 67, 1544–1554.
Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA and Easton DF . (1999). Cancer Epidemiol. Biomarkers Prev., 8, 843–854.
Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A and Benhamou S . (2002). Cancer Epidemiol. Biomarkers Prev., 11, 1550–1554.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M and the Breast Cancer Linkage Consortium. (1998). Am. J. Hum. Genet., 62, 676–689.
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B and King MC . (1990). Science, 250, 1684–1689.
Heijmans BT, Boer JM, Suchiman HE, Cornelisse CJ, Westendorp RG, Kromhout D, Feskens EJ and Slagboom PE . (2003). Cancer Res., 63, 1249–1253.
Houlston RS and Peto J . (2003). Hum. Genet., 112, 434–435.
Houlston RS and Tomlinson IP . (2001). Gastroenterology, 121, 282–301.
Kruglyak L . (1999). Nat. Genet., 22, 139–144.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki K . (2000). N. Engl. J. Med., 343, 78–85.
Lindbolm A, Tannergaard P, Werelius B and Nordenskjoid B . (1993). Nat. Genet., 5, 279–282.
Marcus PM, Vineis P and Rothman N . (2000). Pharmacogenetics, 10, 115–122.
Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N and Stratton MR . (2002). Nat. Genet., 31, 55–59.
Morton NE, Zhang W, Taillon-Miller P, Ennis S, Kwok PY and Collins A . (2001). Proc. Natl. Acad. Sci. USA., 98, 5217–5221.
Ntais C, Polycarpou A and Ioannidis JP . (2003). Cancer Epidemiol. Biomarkers Prev., 12, 20–26.
Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Green JS, Jass JR, Weber JL, Leach FS, Petersen GM, Hamilton SR, de la Chapelle A and Vogelstein B . (1993). Science, 260, 810–812.
Peto J . (1980). Banbury Report 4: Cancer Incidence In Defined Populations Cairns J, Lyon JL and Skolnick MH (eds) Cold Spring Harbor Laboratories: Cold Spring Harbor, New York, pp. 203–213.
Peto J . (2002). Cancer Cell, 1, 411–412.
Peto J, Easton DF, Matthews FE, Ford D and Swerdlow AJ . (1996). Int. J. Cancer, 65, 275–283.
Peto J and Mack TM . (2000). Nat. Genet., 26, 411–414.
Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF and Ponder BA . (2002). Nat. Genet., 31, 33–36.
Ponder BA . (2001). Nature, 411, 336–341.
Pritchard JK, Stephens M, Rosenberg NA and Donnelly P . (2000). Am. J. Hum. Genet., 67, 170–181.
Rapley EA, Crockford GP, Teare D, Biggs P, Seal S, Barfoot R, Edwards S, Hamoudi R, Heimdal K, Fossa SD, Tucker K, Donald J, Collins F, Friedlander M, Hogg D, Goss P, Heidenreich A, Ormiston W, Daly PA, Forman D, Oliver TD, Leahy M, Huddart R, Cooper CS, Bodmer JG, Easton DF, Stratton MR and Bishop DT . (2000). Nat. Genet., 24, 197–200.
Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R and Lander ES . (2001). Nature, 411, 199–204.
Risch N and Merikangas K . (1996). Science, 273, 1516–1517.
Risch N and Teng J . (1998). Genome Res., 8, 1273–1288.
Rostami-Hodjegan A, Lennard MS, Woods HF and Tucker GT . (1998). Pharmacogenetics, 8, 227–238.
Weston A and Godbold JH . (1997). Environ. Health Perspect., 105 (Suppl 4), 919–926.
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T and Averill D et al. (1994). Science, 265, 2088–2090.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Houlston, R., Peto, J. The search for low-penetrance cancer susceptibility alleles. Oncogene 23, 6471–6476 (2004). https://doi.org/10.1038/sj.onc.1207951
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207951
Keywords
This article is cited by
-
Structural insights and evaluation of the potential impact of missense variants on the interactions of SLIT2 with ROBO1/4 in cancer progression
Scientific Reports (2020)
-
Functional Landscape of Common Variants Associated with Susceptibility to Epithelial Ovarian Cancer
Current Epidemiology Reports (2020)
-
Rate of individuals with clearly increased radiosensitivity rise with age both in healthy individuals and in cancer patients
BMC Geriatrics (2018)
-
Telomere length and genetics are independent colorectal tumour risk factors in an evaluation of biomarkers in normal bowel
British Journal of Cancer (2018)
-
Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients
Human Genomics (2017)